ArticlePediatrics2026
SARS-CoV-2 Vaccination Before and During Pregnancy and Prevention of Infant COVID-19 Infection.
Article in Pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundSARS-CoV-2 vaccination during pregnancy reduces COVID-19 risk in infancy. Whether maternal vaccination before pregnancy similarly protects infants against COVID-19 is unknown.
methodsWe examined the effectiveness of maternal messenger RNA SARS-CoV-2 vaccination before and during pregnancy in preventing COVID-19 in infants aged 0-6 months born between July 1, 2021, and June 30, 2023, at Kaiser Permanente Northern California. Maternal vaccination status was categorized as vaccinated during pregnancy, during a prepregnancy interval (0-<3, 3-<6, 6-12, and >12 months prepregnancy), or unvaccinated. Secondary analyses examined the effectiveness of vaccination by trimester. COVID-19 was defined by positive SARS-CoV-2 PCR result or diagnostic code, and COVID-19-related hospitalizations were confirmed by medical record review. Vaccine effectiveness (VE) was examined by Cox regression models adjusted for maternal and infant characteristics, calculated as (1 - hazard ratio) × 100%.
resultsAmong 78 644 infants, 3648 (4.6%) had COVID-19 infection and 76 (0.1%) experienced COVID-19-related hospitalization before age 6 months. For the 4 prepregnancy vaccination intervals, estimates for VE against COVID-19 infection ranged from -14.9% (95% CI, -32.8% to 0.5%) for less than 3 months prepregnancy to 23.6% (-14.3% to 49%) for more than 12 months prepregnancy. VE anytime during pregnancy was 7.5% (-2% to 16.2%) against infant COVID-19 infection and 52.9% (11.1%-75.1%) against infant COVID-19-related hospitalization. Effectiveness of third-trimester vaccination was 19.2% (8.6%-28.6%) against infant COVID-19 infection and 64.6% (12.3%-85.7%) against infant COVID-19-related hospitalizations.
conclusionMaternal vaccination during the third trimester was protective against infant COVID-19 infections. Maternal vaccination during pregnancy, particularly during the third trimester, was effective against infant COVID-19-related hospitalizations. Vaccination before pregnancy did not protect infants.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.